Reduced sexual desire is one of the most common sexual health concerns reported by women in perimenopause and postmenopause, and one of the least discussed in clinical settings. Treatments often fail because they are applied to a multifactorial problem as though it has a single cause.

Low desire in midlife is not simply a hormone deficiency to be corrected, though hormonal factors are real and relevant. It is a confluence of physical changes, psychological shifts, relationship dynamics, and sleep disruption, each of which responds to different interventions.

The Physical Drivers

Genitourinary syndrome of menopause (GSM). The most commonly overlooked physical driver of reduced desire is pain. Estrogen withdrawal causes the thinning, drying, and reduced elasticity of vaginal tissue, producing pain during penetrative sex. Pain during sex is a learned deterrent. The brain and body do not pursue experiences that are reliably uncomfortable, and anticipatory anxiety about pain reduces desire before any physical contact occurs.

Research consistently finds that when dyspareunia from GSM is treated effectively (with local vaginal estrogen, vaginal moisturisers, or ospemifene) sexual desire frequently recovers without additional intervention.[1] The desire problem was never hormonal; it was a rational response to pain. This is the most clinically important physical driver to assess and treat first.

Sleep deprivation. Chronic sleep fragmentation, common in perimenopause, reduces libido through multiple pathways: lowered testosterone (poor sleep reduces gonadotropin secretion and testosterone production), elevated cortisol (which suppresses sex hormone production), and a general reduction in the capacity for positive emotion and reward-seeking. Persistent exhaustion deprioritises non-essential reward-seeking in response to energy deficit; libido is not broken, it is rationed.

Depression and anxiety. Mood disorders have significantly elevated prevalence during perimenopause. Both depression and anxiety directly suppress sexual desire. Anhedonia (loss of the capacity to experience pleasure) is a core feature of depression that includes but is not limited to sexual desire. Treating the mood disorder often partially or fully restores sexual interest.

The Relational Drivers

A 2024 systematic review examining women's experiences of sexuality during the menopausal transition found that relational factors are central to the sexual desire narrative of this life stage.[2] Several patterns emerged consistently.

Partner dynamics. When resentment, poor communication, or reduced emotional intimacy characterises a relationship, testosterone therapy does not restore desire. Sexual desire in women is more context-dependent and relationship-responsive than in men, and no pharmacological intervention compensates for a relational environment that is not conducive to it.

Body image and identity shifts. The physical changes of midlife (weight redistribution, skin changes, altered energy) produce shifts in how women perceive themselves sexually. Women describe feeling less desirable, less at home in their bodies, and disconnected from a sexual identity they held in their 30s. This responds to different interventions than hormonal ones.

Communication about change. Couples who explicitly discuss what is happening during perimenopause (pain, reduced lubrication, the need for different or longer foreplay) adapt more successfully than those who do not. Silence allows both partners to construct unhelpful narratives: one concludes they are no longer attracted to their partner; the other concludes their partner has lost interest in them.

Hormonal Factors

Testosterone. There is solid evidence that transdermal testosterone at physiological female doses improves sexual desire, arousal, and satisfaction in postmenopausal women with hypoactive sexual desire disorder (HSDD). The evidence is specific to HSDD (defined as distressing low desire) and to the postmenopausal context.

Testosterone is not appropriate or effective for low desire driven by pain, relationship dysfunction, depression, or sleep deprivation. The ISSWSH guideline recommends it after other causes have been evaluated.[3]

Estrogen via HRT. Systemic HRT does not directly increase sexual desire or improve orgasmic response, but its indirect effects can be significant. HRT improves sleep, reduces hot flashes, stabilises mood, and at systemic doses can improve genitourinary symptoms. Women who start HRT for vasomotor or sleep reasons often report secondary improvements in sexual well-being as quality of life improves.

Local vaginal estrogen. For women with GSM-related dyspareunia as the primary driver of reduced desire, local estrogen is frequently the most targeted and effective intervention. It does not increase desire through a hormonal mechanism; it removes the physical barrier that suppressed desire.

A Clinical Framework for Treatment

Given the multifactorial nature of reduced desire in midlife, treatment works best when it identifies the specific contributors rather than defaulting to a single intervention.

  1. Is there pain during sex? If yes, address GSM first. Local estrogen, vaginal moisturisers, or ospemifene are appropriate depending on history and preference.
  2. Is sleep severely disrupted? If yes, treating the sleep disruption is more likely to restore libido than any direct sexual intervention.
  3. Is significant depression or anxiety present? If yes, treating the mood disorder takes priority.
  4. Are relationship factors dominant? If yes, couples communication, psychosexual counselling, or therapy is more useful than hormonal treatment.
  5. Is desire reduced despite adequate sleep, no pain, no significant mood disorder, and a supportive relational context? This is the profile for which testosterone has the strongest evidence.

Women who receive accurate guidance about which physical factors are addressable report significantly better sexual well-being outcomes than those who receive no information or who are told that reduced desire is simply a normal consequence of ageing.[2]

References

[1] Simon, J. A., Nappi, R. E., Kingsberg, S. A., Maamari, R., Brown, V. (2014). Clarifying vaginal atrophy's impact on sex and relationships. Menopause, 21(2), 137-142. See also: Management of libido problems in menopause. https://pmc.ncbi.nlm.nih.gov/articles/PMC6220606/

[2] O'Sullivan, A. J., et al. (2024). Women's experiences of intimate and sexual relationships during menopause: a qualitative synthesis. Menopause, 31(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC12037939/

[3] Parish, S. J., Simon, J. A., Davis, S. R., et al. (2021). International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. Journal of Sexual Medicine, 18(5), 849-867. https://pubmed.ncbi.nlm.nih.gov/33797277/